Cite
MLA Citation
Martin Dreyling et al.. “Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study.” American journal of hematology, vol. 95, no. 4, n.d., pp. 362–371. http://access.bl.uk/ark:/81055/vdc_100118065014.0x000048